Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

Xiaolong Qi¹, Yanna Liu², Jitao Wang³, Jonathan A Fallowfield⁴, Jianwen Wang⁵, Xinyu Li⁶, Jindong Shi⁷, Hongqiu Pan⁸, Shengqiang Zou⁸, Hongguang Zhang⁸, Zhenhuai Chen⁹, Fujian Li⁹, Yan Luo¹⁰, Mei Mei¹⁰, Huiling Liu¹⁰, Zhengyan Wang¹¹, Jinlin Li¹¹, Hua Yang¹², Huihua Xiang¹³, Xiaodan Li¹⁴, Tao Liu¹⁵, Ming-Hua Zheng¹⁶, Chuan Liu², Yifei Huang², Dan Xu², Xiaoguo Li², Ning Kang², Qing He¹⁷, Ye Gu¹⁸, Guo Zhang¹⁹, Chuxiao Shao²⁰, Dengxiang Liu³, Lin Zhang²¹, Xun Li²², Norifumi Kawada²³, Zicheng Jiang²⁴, Fengmei Wang²⁵, Bin Xiong²⁶, Tetsuo Takehara²⁷, Don C Rockey²⁸; COVID-Cirrhosis-CHESS Group

Affiliations

¹ CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China qixiaolong@vip.163.com herr_xiong@126.com.
² CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
³ CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
⁴ Centre for Inflammation Research, University of Edinburgh MRC Centre for Inflammation Research, Edinburgh, UK.
⁵ Department of Tuberculosis and Respiratory, Wuhan Jinyintan Hospital, Wuhan, China.
⁶ Department of Infectious Disease, Shanghai Fifth People's Hospital of Fudan University, Shanghai, China.
⁷ Department of Respiratory Medicine, Shanghai Fifth People's Hospital of Fudan University, Shanghai, China.
⁸ Department of Infectious Diseases and Critical Care Medicine, The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China.
⁹ Department of Respiratory Medicine, The People's Hospital of Baoding, Baoding, China.
¹⁰ Department of Gastroenterology, Tianjin Haihe Hospital, Tianjin, China.
¹¹ Department of Respiratory Medicine, Suizhou Hospital, Hubei University of Medicine, Suizhou, China.
¹² Department of Respiratory Medicine, Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China.
¹³ Department of Radiology, Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China.
¹⁴ Department of Infectious Disease, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China.
¹⁵ Department of Infectious Disease, The Central Hospital of Lichuan, Enshi, China.
¹⁶ MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
¹⁷ CHESS-COVID-19 Group, The Third People's Hospital of Shenzhen, Shenzhen, China.
¹⁸ CHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang, Shenyang, China.
¹⁹ CHESS-COVID-19 Group, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
²⁰ CHESS-COVID-19 Group, Zhejiang University Lishui Hospital and Lishui Central Hospital, Lishui, China.
²¹ Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
²² The First Hospital of Lanzhou University, Lanzhou, China.
²³ Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
²⁴ Department of Infectious Disease, Ankang Central Hospital, Ankang, China.
²⁵ Department of Gastroenterology and Hepatology, Tianjin Second People's Hospital, Tianjin, China.
²⁶ Department of Radiology, Wuhan Union Hospital, Wuhan, China qixiaolong@vip.163.com herr_xiong@126.com.
²⁷ Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
²⁸ Division of Gastroenterology and Hepatology, Medical University South Carolina, Charleston, South Carolina, USA.

PMID: 32434831
PMCID: PMC7815629
DOI: 10.1136/gutjnl-2020-321666

Comment

Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

Xiaolong Qi et al. Gut. 2021 Feb.

. 2021 Feb;70(2):433-436.

doi: 10.1136/gutjnl-2020-321666. Epub 2020 May 20.

Authors

Affiliations

¹ CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China qixiaolong@vip.163.com herr_xiong@126.com.
² CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
³ CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
⁴ Centre for Inflammation Research, University of Edinburgh MRC Centre for Inflammation Research, Edinburgh, UK.
⁵ Department of Tuberculosis and Respiratory, Wuhan Jinyintan Hospital, Wuhan, China.
⁶ Department of Infectious Disease, Shanghai Fifth People's Hospital of Fudan University, Shanghai, China.
⁷ Department of Respiratory Medicine, Shanghai Fifth People's Hospital of Fudan University, Shanghai, China.
⁸ Department of Infectious Diseases and Critical Care Medicine, The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China.
⁹ Department of Respiratory Medicine, The People's Hospital of Baoding, Baoding, China.
¹⁰ Department of Gastroenterology, Tianjin Haihe Hospital, Tianjin, China.
¹¹ Department of Respiratory Medicine, Suizhou Hospital, Hubei University of Medicine, Suizhou, China.
¹² Department of Respiratory Medicine, Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China.
¹³ Department of Radiology, Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China.
¹⁴ Department of Infectious Disease, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China.
¹⁵ Department of Infectious Disease, The Central Hospital of Lichuan, Enshi, China.
¹⁶ MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
¹⁷ CHESS-COVID-19 Group, The Third People's Hospital of Shenzhen, Shenzhen, China.
¹⁸ CHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang, Shenyang, China.
¹⁹ CHESS-COVID-19 Group, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
²⁰ CHESS-COVID-19 Group, Zhejiang University Lishui Hospital and Lishui Central Hospital, Lishui, China.
²¹ Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
²² The First Hospital of Lanzhou University, Lanzhou, China.
²³ Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan.
²⁴ Department of Infectious Disease, Ankang Central Hospital, Ankang, China.
²⁵ Department of Gastroenterology and Hepatology, Tianjin Second People's Hospital, Tianjin, China.
²⁶ Department of Radiology, Wuhan Union Hospital, Wuhan, China qixiaolong@vip.163.com herr_xiong@126.com.
²⁷ Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
²⁸ Division of Gastroenterology and Hepatology, Medical University South Carolina, Charleston, South Carolina, USA.

PMID: 32434831
PMCID: PMC7815629
DOI: 10.1136/gutjnl-2020-321666

No abstract available

Keywords: infectious disease; liver cirrhosis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.
Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, Fantini MC, Armuzzi A, Daperno M, Fiorino G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Bezzio C, et al. Gut. 2020 Jul;69(7):1213-1217. doi: 10.1136/gutjnl-2020-321411. Epub 2020 Apr 30. Gut. 2020. PMID: 32354990

References

1. Bezzio C, Saibeni S, Variola A, et al. . Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020;69:1213–7. 10.1136/gutjnl-2020-321411 - DOI - PubMed
1. Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5:428–30. 10.1016/S2468-1253(20)30057-1 - DOI - PMC - PubMed
1. Gacouin A, Locufier M, Uhel F, et al. . Liver cirrhosis is independently associated with 90-day mortality in ARDS patients. Shock 2016;45:16–21. 10.1097/SHK.0000000000000487 - DOI - PubMed
1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020. 10.1001/jama.2020.2648. [Epub ahead of print: 24 Feb 2020] (Epub ahead of print: 24 Feb 2020). - DOI - PubMed
1. Onder G, Rezza G, Brusaferro S. Case-Fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020. 10.1001/jama.2020.4683. [Epub ahead of print: 23 Mar 2020]. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

P30 DK123704/DK/NIDDK NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

Affiliations

Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical